Category: AtriCure Inc.
AtriCure's report of strong sales growth for the 4th quarter and 2013 sends share prices up on Wall Street.
Fresh off of the $34 million acquisition of Estech, AtriCure (NSDQ:ATRC) reported strong sales growth for the 4th quarter and 2013 and predicted even better gains for this year, sending share prices up today on Wall Street.
AtriCure offers $34 million up-front in stock for surgical ablation devices maker Estech, with another $26 million tied to performance-based milestones.
AtriCure (NSDQ:ATRC) signed a definitive agreement with Estech, offering to give the ablation devices maker about $34 million in stock.
AtriCure says the FDA granted an investigational device exemption for a clinical trial of its AtriClip left atrial appendage exclusion device to gauge its utility in preventing stroke in patients with atrial fibrillation.
AtriCure (NSDQ:ATRC) said today that the FDA approved the launch of a clinical trial to examine whether its AtriClip device can be used to prevent strokes in patients with atrial fibrillation.
AtriCure shares are up today after the medical device company reported surging 3rd-quarter sales and raised its outlook for the rest of the year.
AtriCure (NSDQ:ATRC) shares added more than 8% today after the medical device company reported 3r-quarter sales that beat Wall Street's forecast and raised its outlook for the rest of the year.
Ohio medical device maker AtriCure pledges to make "significant investments" into research and education in efforts to improve the lives of 250,000 atrial fibrillation patients by 2020.
AtriCure and Century Medical beef up their Japanese distribution contract for surgical ablation tools, extending exclusivity until 2019.
AtriCure (NSDQ:ATRC) inked a bigger and bolder contract with its Japanese distributor Century Medical Inc., promising its partner exclusive rights for all product lines until 2019.
Despite posting losses in the 2nd quarter, AtriCure shares float on raised guidance.
AtriCure (NSDQ:ATRC) posted slightly wider 2nd-quarter losses but shares remained healthy on Wall Street after the company boosted its guidance.